Literature DB >> 19955764

Prolactinomas in children and adolescents.

Annamaria Colao, Sandro Loche.   

Abstract

Prolactinomas are the most common pituitary adenomas in children and adolescents followed by adrenocorticotropic hormone-secreting and growth hormone-secreting adenomas. Females are slightly more affected than males (who have macroadenomas more frequently). Compared with the adult setting, in children macroadenomas are more frequent than microadenomas. Diagnosis is generally based on clinical symptoms of primary or secondary gonadal failure, growth delay and/or tumor compressive symptoms. Treatment is based on medical therapy with dopamine agonists, to control prolactin levels and reduce tumor size. Surgery is indicated in patients with tumors resistant to dopamine agonists as well as in those showing severe neurological symptoms at diagnosis. Radiotherapy should be limited to the cases with aggressive tumors, nonresponsive to dopamine agonists, because of the risk of neurological damage and hypopituitarism later in the lives of these patients. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955764     DOI: 10.1159/000262536

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  7 in total

1.  Prolactinomas in children under 14. Clinical presentation and long-term follow-up.

Authors:  Yang Liu; Yong Yao; Bing Xing; Wei Lian; Kan Deng; Ming Feng; Renzhi Wang
Journal:  Childs Nerv Syst       Date:  2015-03-15       Impact factor: 1.475

2.  Non-functioning pituitary microadenoma in children and adolescents: Is follow-up with diagnostic imaging necessary?

Authors:  Maria Elfving; Margareta Nilsson; Camilla Borghammar; Ashkan Tamaddon; Eva-Marie Erfurth; Pia C Sundgren; Peter Siesjö
Journal:  Endocrine       Date:  2022-10-17       Impact factor: 3.925

3.  Characteristics and overall survival in pediatric versus adult pituitary adenoma: a National Cancer Database analysis.

Authors:  Benjamin F Bitner; Brandon M Lehrich; Arash Abiri; Tyler M Yasaka; Frank P K Hsu; Edward C Kuan
Journal:  Pituitary       Date:  2021-04-30       Impact factor: 4.107

4.  Expression of cyclooxygenase-2 (COX-2) in pituitary tumours.

Authors:  Grzegorz Sokołowski; Agata Bałdys-Waligórska; Małgorzata Trofimiuk; Dariusz Adamek; Alicja Hubalewska-Dydejczyk; Filip Gołkowski
Journal:  Med Sci Monit       Date:  2012-04

5.  Pediatric pituitary adenomas in Northeast Mexico. A follow-up study.

Authors:  Lucia Torres-García; Ricardo M Cerda-Flores; Marcela Márquez
Journal:  Endocrine       Date:  2018-08-31       Impact factor: 3.633

6.  Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.

Authors:  Chao Tang; Ruixin Sun; Guodao Wen; Chunyu Zhong; Jin Yang; Junhao Zhu; Zixiang Cong; Xiaoying Luo; Chiyuan Ma
Journal:  Cell Death Dis       Date:  2019-04-18       Impact factor: 8.469

7.  Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.

Authors:  Aram Yang; Sung Yoon Cho; Hyojung Park; Min Sun Kim; Doo-Sik Kong; Hyung-Jin Shin; Dong-Kyu Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-04       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.